Literature DB >> 12521564

Current Therapies for Paraneoplastic Neurologic Syndromes.

Myrna R. Rosenfeld1, Josep Dalmau.   

Abstract

Paraneoplastic neurologic syndromes (PNS) comprise an extensive group of heterogeneous disorders that can affect any part of the central and peripheral nervous system. There is evidence that many of these disorders are mediated by immunologic responses triggered by the presence of a cancer. Several immunologic mechanisms and many antigenic targets have been related to these disorders. Some disorders of the neuromuscular junction or peripheral nervous system are directly mediated by antibodies, and they may have a paraneoplastic origin or develop without a tumor association. For these disorders and a few PNS of the central nervous system, immunotherapy may result in neurologic improvement. However, for most PNS of the peripheral and central nervous system the response to any type of therapy is, in general, disappointing. The main concern of the clinician should be to rule out other diagnostic entities and to uncover the presence of the associated neoplasm that often remains elusive to detection. In general, the best approach to treat PNS is to discover and treat the tumor promptly, and provide supportive care for the neurologic deficits with symptomatic treatment and physical therapy. In a few cases, depending on the syndrome and if the patient is in the early stages of the neurologic disease, treatment with immunosuppression may have some effect on the PNS.

Entities:  

Year:  2003        PMID: 12521564     DOI: 10.1007/s11940-003-0023-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  43 in total

1.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

2.  Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.

Authors:  J Dalmau; F Graus; M K Rosenblum; J B Posner
Journal:  Medicine (Baltimore)       Date:  1992-03       Impact factor: 1.889

3.  Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.

Authors:  T Byrne; W P Mason; J B Posner; J Dalmau
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

4.  Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.

Authors:  L Bataller; F Graus; A Saiz; J J Vilchez
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

5.  Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders.

Authors:  F Blaes; M Strittmatter; S Merkelbach; V Jost; M Klotz; K Schimrigk; G F Hamann
Journal:  J Neurol       Date:  1999-04       Impact factor: 4.849

6.  Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  B Benyahia; R Liblau; H Merle-Béral; J M Tourani; J Dalmau; J Y Delattre
Journal:  Ann Neurol       Date:  1999-02       Impact factor: 10.422

7.  Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome.

Authors:  W G Mitchell; S R Snodgrass
Journal:  J Child Neurol       Date:  1990-04       Impact factor: 1.987

8.  Limbic encephalopathy as a nonmetastatic complication of oat cell lung cancer. Its reversal after treatment of the primary lung lesion.

Authors:  L V Brennan; P R Craddock
Journal:  Am J Med       Date:  1983-09       Impact factor: 4.965

9.  Neuropathy and motor neuron syndromes associated with plasma cell disease.

Authors:  B M Patten
Journal:  Acta Neurol Scand       Date:  1984-07       Impact factor: 3.209

10.  Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma.

Authors:  P S Koh; J G Raffensperger; S Berry; M B Larsen; H S Johnstone; P Chou; S R Luck; M Hammer; S L Cohn
Journal:  J Pediatr       Date:  1994-11       Impact factor: 4.406

View more
  6 in total

1.  Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature.

Authors:  Takashi Taketa; Seiji Ohigashi; Koyu Suzuki; Kazuki Sudo; Hironori Shiozaki; Akihiro Suzuki; Mariela A Blum; Jaffer A Ajani; Hisashi Onodera
Journal:  Clin J Gastroenterol       Date:  2012-08-28

Review 2.  Paraneoplastic syndromes in prostate cancer.

Authors:  Matthew K Hong; Jennifer Kong; Benjamin Namdarian; Anthony Longano; Jeremy Grummet; Christopher M Hovens; Anthony J Costello; Niall M Corcoran
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

3.  Paraneoplastic neurological syndrome in a patient with gastric cancer.

Authors:  Hitoshi Murakami; Yasushi Rino; Shoji Yamanaka; Yasuhisa Baba; Takashi Sekiguchi; Norio Yukawa; Takashi Oshima; Nobuhiro Sugano; Hitoshi Matsuura; Munetaka Masuda; Toshio Imada
Journal:  Gastric Cancer       Date:  2010-09-05       Impact factor: 7.370

Review 4.  Clinical applications of a peptide-based vaccine for glioblastoma.

Authors:  Charles W Kanaly; Dale Ding; Amy B Heimberger; John H Sampson
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

5.  CV2/CRMP5-antibody-related Paraneoplastic Neurologic Syndrome Associated with Gastrointestinal Stromal Tumor.

Authors:  Hirofumi Fukushima; Tomoyoshi Shibuya; Takahito Awatsu; Taro Kurosawa; Keiichi Haga; Takashi Murakami; Nobuko Serizawa; Akio Mori; Mariko Hojo; Takashi Yao; Nobutaka Hattori; Akihito Nagahara
Journal:  Intern Med       Date:  2021-10-19       Impact factor: 1.282

6.  Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy.

Authors:  Joanna Zurko; Amitkumar Mehta
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.